EMET
Agentic research environment
The agentic research environment for R&D, unifying data, models, software packages, workflows, lab-in-the-loop and scientific reasoning into a single environment purpose-built for R&D.
Learn more Source
BenchSci
AIToronto, ON
Builds AI software (ASCEND, and newly EMET) that helps pharma R&D scientists mine scientific literature and biological data to speed preclinical drug discovery.
Canadian innovation builds a brighter tomorrow.
About
Company site: benchsci.comBuilds AI software (ASCEND, and newly EMET) that helps pharma R&D scientists mine scientific literature and biological data to speed preclinical drug discovery.
Raised $95M CAD (US$70M) Series D led by Generation Investment Management, bringing total funding to $218M CAD (May 2023). betakit.com
Signed a three-year license agreement with Sanofi for global preclinical deployment of its ASCEND platform (October 2025). benchsci.com
Renewed a two-year contract with Merck (MSD) extending ASCEND access for preclinical disease biology research (December 2025). benchsci.com
Named former Pfizer R&D chief Dr. Mikael Dolsten as its first-ever Board Chairman, effective June 2026. benchsci.com
Products & Services
Company site: benchsci.comProducts BenchSci publishes on its own site. Each card links to the page it was taken from.
Funding & Investors
Announced rounds only, newest first. Undisclosed amounts are shown as undisclosed.
Series D
May 25, 2023
C$95.0Mbetakit.comInvestors: Generation Investment Management, Inovia Capital, TCV, Golden Ventures, F-Prime Capital
Series C
Jan 24, 2022
C$63.0Mbetakit.comInvestors: Inovia Capital, TCV, Northleaf Capital Partners, Gradient Ventures, Golden Ventures
Series B
Feb 4, 2020
C$29.0Mbetakit.comInvestors: F-Prime Capital, Northleaf Capital Partners, Gradient Ventures, Inovia Capital, Golden Ventures, Real Ventures
Series A extension
Jun 26, 2019
C$6.7Mbetakit.comInvestors: Gradient Ventures
Series A ($10M)
May 2, 2018
Undisclosedbetakit.comInvestors: iNovia Capital, Gradient Ventures, Golden Venture Partners, Afore Capital, Real Ventures, Radical Ventures
Total disclosed: C$193.7MLatest: Series D · May 25, 2023
Partnerships
Publicly announced partnerships.
Thermo Fisher Scientific
Strategic partnership to build AI-enabled tools: enterprise software for scientific instruments, literature search, and reagent selection (2025).
Sanofi
Three-year license agreement giving Sanofi's global preclinical research organization access to BenchSci's ASCEND platform (2025).
Mila
Multi-year research partnership to develop AI for biological inference and experimental assay prediction in drug discovery (2025).
Merck
Renewed two-year contract continuing Merck's access to ASCEND for preclinical disease biology research (2025).
Novartis
Expansion of an existing contract with Novartis, announced alongside the February 2020 Series B.
argenx
Two-year enterprise agreement under which scientists across argenx's global research organization will use EMET for preclinical, computational and drug development workflows (September 2026).
Google Cloud
EMET will run on Google Cloud as its primary infrastructure, with work under way to list EMET on Google Cloud Marketplace (August 2026).
People
Sourced from the company's own pages or announcements.
Liran Belenzon
Co-founder & CEO
Tom Leung
Co-founder & Chief Science Officer
Elvis Wianda
Co-founder & Chief Data Officer
David Chen
Co-founder
John Jackson
Chief Technology Officer
Similar Companies
Other companies in AI.
